Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

DBV Technologies (DBV)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.19 -0.01    -1.17%
26/04 - Closed. Currency in EUR ( Disclaimer )
  • Volume: 37,915
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 1.18 - 1.20
Type:  Equity
Market:  France
ISIN:  FR0010417345 
DBV Technologies 1.19 -0.01 -1.17%

DBV Technologies Company Profile

 
Read the DBV Technologies company profile to learn more about the business and the management team. View DBV Technologies facts about employee data, company products and services, and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

105

Equity Type

ORD

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Contact Information

Address 177-181 Avenue Pierre Brossolette
Montrouge, 92120
France
Phone 33 1 55 42 78 78
Fax 33 1 43 26 10 83

Top Executives

Name Age Since Title
Pierre-Henri Benhamou 66 2002 Co-Founder & Member of Scientific Advisory Board
Gideon Lack - - Member of the Scientific Advisory Board
Jonathan M. Spergel - - Member of the Scientific Advisory Board
Michael Rosenblum - 2019 Member of Scientific Advisory Board
Christophe Dupont - - Member of Advisory Board
Ravi Madduri Rao 55 2021 Independent Director
Emma Guttman-Yassky - 2019 Member of Scientific Advisory Board
Jim Krueger - 2019 Member of Scientific Advisory Board
Miriam Merad - 2019 Member of Scientific Advisory Board
Jean-François Nicolas - 2019 Member of Scientific Advisory Board
Adora Ndu 41 2021 Independent Director
Betty A. Diamond - 2021 Member of Scientific Advisory Board
Daniele Guyot-Caparros 64 2022 Independent Director
Michel de Rosen 72 2018 Independent Chairman of the Board
Hugh A. Sampson 74 2015 Scientific Adviser to the CEO & Chairman of Scientific Advisory Board
Michael J. Goller 48 2015 Director
Daniel Tassé 63 2018 CEO & Director
Mailys Ferrere 61 2012 Director
Paul-Henri Lambert 84 - Member of the Scientific Advisory Board
Daniel B. Soland 67 2015 Independent Director
Timothy E. Morris 62 2021 Independent Director
Julie O'Neill 57 2017 Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

DBV Price Commentary

Write your thoughts about DBV Technologies
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email